After Eli Lilly (LLY) reported Q3 results that are below the Street view on sales and EPS due to Zepbound and Mounjaro wholesaler destocking and narrowed its top-line guidance to $45.4B-$46.0B while maintaining its EPS guidance ex-IPRD of $16.10-$16.60, JPMorgan assumes shares will be off on today’s results. However, Lilly “remains one of our favorite names in the group” and the firm sees further upside to Street estimates as injectable capacity ramps, orforglipron comes to market and outcomes data support broad use of obesity medications, says the analyst, who maintains an Overweight rating on shares and will look for more color during the call.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Options Volatility and Implied Earnings Moves Today, October 30, 2024
- Eli Lilly cuts FY24 EPS view to $13.02-$13.52 from $16.10-$16.60
- Eli Lilly reports Q3 EPS $1.18, consensus $1.47
- Notable companies reporting before tomorrow’s open
- Eli Lilly says Donanemab redudced ARIA-E in early Alzheimer’s patients